Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 254,125 shares of the company’s stock after buying an additional 82,068 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Medpace were worth $77,897,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Contravisory Investment Management Inc. acquired a new position in Medpace during the 4th quarter valued at about $26,000. RiverPark Advisors LLC bought a new stake in Medpace during the fourth quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in Medpace in the fourth quarter worth approximately $30,000. McGlone Suttner Wealth Management Inc. bought a new position in Medpace during the 4th quarter valued at $33,000. Finally, FinTrust Capital Advisors LLC acquired a new position in shares of Medpace during the 3rd quarter valued at $30,000. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MEDP. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and upped their price target for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Robert W. Baird raised their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Guggenheim boosted their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $0.89 during midday trading on Thursday, reaching $396.97. The company had a trading volume of 101,782 shares, compared to its average volume of 249,280. The company has a fifty day simple moving average of $398.32 and a two-hundred day simple moving average of $328.94. The firm has a market cap of $12.30 billion, a price-to-earnings ratio of 40.79, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.27 earnings per share. Analysts expect that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Insider Activity at Medpace

In other Medpace news, Director Ashley M. Keating sold 250 shares of Medpace stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the transaction, the director now directly owns 250 shares in the company, valued at approximately $102,467.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ashley M. Keating sold 250 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now directly owns 250 shares of the company’s stock, valued at $102,467.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 204,442 shares of company stock worth $82,702,867. 20.30% of the stock is owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.